About Adiponectin receptor protein 2
Adiponectin receptor protein 2 (ADIPOR2) is a protein
from Homo sapiens identified by UniProt accession
Q86V24, 386 residues long.
MolForge cross-references it against 0 known binders and
346 disease associations.
Target properties
| Protein name | Adiponectin receptor protein 2 |
|---|
| UniProt accession | Q86V24 |
|---|
| Gene | ADIPOR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 386 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (346)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.31
- lymphocyte count · score 0.27
- mean corpuscular volume · score 0.26
- mean reticulocyte volume · score 0.25
- mean platelet volume · score 0.20
- lung adenocarcinoma · score 0.19
- MODY · score 0.10
- azoospermia · score 0.09
- type 2 diabetes mellitus · score 0.09
- partial chromosome Y deletion · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86V24-F1 | alphafold | PREDICTED | 82.50 | — |
Amino-acid sequence (386 residues)
MNEPTENRLG CSRTPEPDIR LRKGHQLDGT RRGDNDSHQG DLEPILEASV LSSHHKKSSE EHEYSDEAPQ EDEGFMGMSP LLQAHHAMEK MEEFVCKVWE GRWRVIPHDV LPDWLKDNDF LLHGHRPPMP SFRACFKSIF RIHTETGNIW THLLGCVFFL CLGIFYMFRP NISFVAPLQE KVVFGLFFLG AILCLSFSWL FHTVYCHSEG VSRLFSKLDY SGIALLIMGS FVPWLYYSFY CNPQPCFIYL IVICVLGIAA IIVSQWDMFA TPQYRGVRAG VFLGLGLSGI IPTLHYVISE GFLKAATIGQ IGWLMLMASL YITGAALYAA RIPERFFPGK CDIWFHSHQL FHIFVVAGAF VHFHGVSNLQ EFRFMIGGGC SEEDAL
Explore Adiponectin receptor protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets